Biopharmaceutical company MorphoSys announced on June 6th local time that it has decided to appoint Arkadius Pichota as its new CEO. Pichota was previously the president of NavigateBioPharma Services, a subsidiary of Novartis AG. The company also announced the appointment of Lukas Gilgen as its new CFO. Gilgen was previously responsible for corporate transactions at Novartis AG. In February, Novartis AG announced that it would acquire German-based biopharmaceutical company MorphoSys for 2.7 billion euros, adding its cancer treatment drugs to its product line.
MorphoSys任命诺华高管为新任CEO和CFO
MorphoSys appoints nov inc executives as new CEO and CFO.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.